{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:28:11Z","timestamp":1793377691020,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1053\/j.semnuclmed.2024.09.001","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T23:14:56Z","timestamp":1728083696000},"page":"812-826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Update on 18F-Fluoroestradiol"],"prefix":"10.1053","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2685-101X","authenticated-orcid":false,"given":"Sophia R.","family":"O'Brien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Edmonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca E.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil K.","family":"Taunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin R.","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6971-5413","authenticated-orcid":false,"given":"David A.","family":"Mankoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1053\/j.semnuclmed.2024.09.001_bib0001","first-page":"1212","article-title":"Preparation of four fluorine- 18-labeled estrogens and their selective uptakes in target tissues of immature rats","volume":"25","author":"Kiesewetter","year":"1984","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.09.001_bib0002","unstructured":"FDA. Cerianna (Fluoroestradiol F18) Full Prescribing Information.; 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212155s000lbl.pdf. Accessed August 1, 2024"},{"key":"10.1053\/j.semnuclmed.2024.09.001_bib0003","unstructured":"Fluroestradiol (18F) ESTROTEP 500 MBq\/mL solution for injection Reevaluation, 2020. https:\/\/www.has-sante.fr\/jcms\/p_3161190\/en\/estrotep-fluoroestradiol-18f. Accessed August 1, 2024"},{"key":"10.1053\/j.semnuclmed.2024.09.001_bib0004","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nucmedbio.2020.02.007","article-title":"The quest for improving the management of breast cancer by functional imaging: the discovery and development of 16alpha-[ (18)F]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review","volume":"92","author":"Katzenellenbogen","year":"2021","journal-title":"Nucl Med Biol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.09.001_bib0005","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0969-8051(97)00002-4","article-title":"Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16 alpha-fluoroestradiol (FES)","volume":"24","author":"Mankoff","year":"1997","journal-title":"Nucl Med Biol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.09.001_bib0006","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2967\/jnumed.123.266938","article-title":"Summary: SNMMI procedure standard\/EANM practice guideline for estrogen receptor imaging of patients with breast cancer using 16alpha-[ (18)F]Fluoro-17beta-estradiol PET","volume":"65","author":"Mankoff","year":"2024","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.09.001_bib0007","first-page":"679","article-title":"[18F]fluoroestradiol radiation dosimetry in human PET studies","volume":"42","author":"Mankoff","year":"2001","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.09.001_bib0008","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2967\/jnumed.116.175596","article-title":"18F-fluoroestradiol PET: current status and potential future clinical applications","volume":"57","author":"Liao","year":"2016","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.09.001_bib0009","article-title":"18)F-fluoroestradiol: current applications and future directions","volume":"43","author":"O'Brien","year":"2023","journal-title":"Radiographics"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.09.001_bib0010","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.nucmedbio.2011.03.002","article-title":"Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer","volume":"38","author":"Peterson","year":"2011","journal-title":"Nucl Med Biol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.09.001_bib0011","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1148\/radiology.169.1.3262228","article-title":"Breast cancer: PET imaging of estrogen receptors","volume":"169","author":"Mintun","year":"1988","journal-title":"Radiology"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.09.001_bib0012","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2967\/jnumed.107.047506","article-title":"Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol","volume":"49","author":"Peterson","year":"2008","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.09.001_bib0013","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1470-2045(18)30936-7","article-title":"Diagnostic accuracy and safety of 16\u03b1-[ (18)F]fluoro-17\u03b2-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study","volume":"20","author":"SY","year":"2019","journal-title":"Lancet Oncol"},{"issue":"31","key":"10.1053\/j.semnuclmed.2024.09.001_bib0014","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.00400","article-title":"Clinical validity of 16alpha-[ (18)F]Fluoro-17beta-estradiol positron emission tomography\/computed tomography to assess estrogen receptor status in newly diagnosed metastatic breast cancer","volume":"40","author":"van Geel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1053\/j.semnuclmed.2024.09.001_bib0015","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1200\/JCO.2005.04.3810","article-title":"Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer","volume":"24","author":"Linden","year":"2006","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.09.001_bib0016","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1200\/JCO.2001.19.11.2797","article-title":"Metabolic flare: indicator of hormone responsiveness in advanced breast cancer","volume":"19","author":"Mortimer","year":"2001","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1053\/j.semnuclmed.2024.09.001_bib0017","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1158\/1078-0432.CCR-10-3321","article-title":"Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer","volume":"17","author":"Linden","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.09.001_bib0018","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2967\/jnumed.114.147579","article-title":"Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16\u03b1-18F-fluoro-17\u03b2-estradiol PET\/CT","volume":"56","author":"van Kruchten","year":"2015","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.09.001_bib0019","doi-asserted-by":"crossref","first-page":"636","DOI":"10.2967\/jnumed.120.244319","article-title":"Prognostic value of 16\u03b1- (18)F-Fluoro-17\u03b2-Estradiol PET as a predictor of disease outcome in endometrial cancer: a prospective study","volume":"62","author":"Yamada","year":"2021","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.09.001_bib0020","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.4103\/jcrt.JCRT_1075_16","article-title":"Estrogen and progesterone receptor in meningiomas: an immunohistochemical analysis","volume":"16","author":"Telugu","year":"2020","journal-title":"J Cancer Res Ther"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.09.001_bib0021","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13550-019-0549-y","article-title":"Enhanced pulmonary uptake on (18)F-FES-PET\/CT scans after irradiation of the thoracic area: related to fibrosis?","volume":"9","author":"Venema","year":"2019","journal-title":"EJNMMI Res"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.09.001_bib0022","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1097\/RLU.0000000000004788","article-title":"18 F-FES uptake in radiation pneumonitis","volume":"48","author":"Mahalik","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.09.001_bib0023","doi-asserted-by":"crossref","first-page":"990","DOI":"10.2967\/jnumed.123.266511","article-title":"[ (18)F]Fluoroestradiol uptake in irradiated lung parenchyma and draining nodes","volume":"65","author":"Rich","year":"2024","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.09.001_bib0024","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.3390\/diagnostics11112019","article-title":"Analyzing the estrogen receptor status of liver metastases with [ (18)F]-FES-PET in patients with breast cancer","volume":"11","author":"Boers","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.09.001_bib0025","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2967\/jnumed.123.265420","article-title":"Summary: appropriate use criteria for estrogen receptor-targeted PET imaging with 16alpha- (18)f-fluoro-17beta-fluoroestradiol","volume":"64","author":"Ulaner","year":"2023","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.09.001_bib0026","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/cncy.22226","article-title":"Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: a comparison between FNA cell blocks and decalcified core needle biopsies","volume":"128","author":"Zeng","year":"2020","journal-title":"Cancer Cytopathol"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.09.001_bib0027","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3109\/0284186X.2012.754990","article-title":"Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer","volume":"52","author":"Aurilio","year":"2013","journal-title":"Acta Oncol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.09.001_bib0028","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2967\/jnumed.111.092734","article-title":"PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma","volume":"53","author":"van Kruchten","year":"2012","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1053\/j.semnuclmed.2024.09.001_bib0029","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.2967\/jnumed.120.256826","article-title":"Value of (18)F-FES PET in solving clinical dilemmas in breast cancer patients: a retrospective study","volume":"62","author":"Boers","year":"2021","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.09.001_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116341","article-title":"The preliminary study of 16alpha-[18F]fluoroestradiol PET\/CT in assisting the individualized treatment decisions of breast cancer patients","volume":"10","author":"Sun","year":"2015","journal-title":"PLoS One"},{"issue":"9","key":"10.1053\/j.semnuclmed.2024.09.001_bib0031","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.21037\/qims-20-1364","article-title":"The clinical value of (18)F-fluoroestradiol in assisting individualized treatment decision in dual primary malignancies","volume":"11","author":"Yang","year":"2021","journal-title":"Quant Imaging Med Surg"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.09.001_bib0032","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"NCCN clinical practice guidelines in oncology breast cancer version 4.2024","volume":"22","author":"WJea","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.09.001_bib0033","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/bcr2645","article-title":"Receptor conversion in distant breast cancer metastases","volume":"12","author":"Hoefnagel","year":"2010","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.09.001_bib0034","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s12032-010-9418-2","article-title":"Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent\/metastatic lesions of patients with breast cancer","volume":"28","author":"Sari","year":"2011","journal-title":"Med Oncol"},{"key":"10.1053\/j.semnuclmed.2024.09.001_bib0035","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx363.030","article-title":"Molecular imaging with 18F-fluoroestradiol (18F-FES) to assess intrapatient heterogeneity in metastatic breast cancer (MBC): a European TRANSCAN program","volume":"28","author":"Gennari","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.09.001_bib0036","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/annonc\/mds248","article-title":"Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis","volume":"24","author":"Dieci","year":"2013","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1053\/j.semnuclmed.2024.09.001_bib0037","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.3390\/cancers14143531","article-title":"Chemotherapy shows a better efficacy than endocrine therapy in metastatic breast cancer patients with a heterogeneous estrogen receptor expression assessed by (18)F-FES PET","volume":"14","author":"Xie","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2024.09.001_bib0038","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2019.10.024","article-title":"Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition","volume":"126","author":"Boers","year":"2020","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.09.001_bib0039","first-page":"422","article-title":"Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer","volume":"37","author":"van de Ven","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.semnuclmed.2024.09.001_bib0040","series-title":"NCCN Guidelines Version 4.2023 Breast Cancer","year":"2023"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.09.001_bib0041","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1001\/jama.289.11.1421","article-title":"Trends in incidence rates of invasive lobular and ductal breast carcinoma","volume":"289","author":"Li","year":"2003","journal-title":"JAMA"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.09.001_bib0042","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1200\/JCO.2003.03.088","article-title":"Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998","volume":"21","author":"Li","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.09.001_bib0043","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cell.2015.09.033","article-title":"Comprehensive molecular portraits of invasive lobular breast cancer","volume":"163","author":"Ciriello","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.09.001_bib0044","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13058-015-0519-x","article-title":"Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics","volume":"17","author":"McCart Reed","year":"2015","journal-title":"Breast Cancer Res"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.09.001_bib0045","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/jbi\/wbab015","article-title":"Accuracy of preoperative breast MRI versus conventional imaging in measuring pathologic extent of invasive lobular carcinoma","volume":"3","author":"Hovis","year":"2021","journal-title":"J Breast Img"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.09.001_bib0046","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jamcollsurg.2018.01.045","article-title":"Evaluating the impact of breast density on preoperative MRI in invasive lobular carcinoma","volume":"226","author":"Wong","year":"2018","journal-title":"J Am Coll Surg"},{"issue":"12","key":"10.1053\/j.semnuclmed.2024.09.001_bib0047","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1001\/jamasurg.2014.926","article-title":"Repeat surgery after breast conservation for the treatment of stage 0 to II breast carcinoma: a report from the National Cancer Data Base, 2004-2010","volume":"149","author":"Wilke","year":"2014","journal-title":"JAMA Surg"},{"issue":"20","key":"10.1053\/j.semnuclmed.2024.09.001_bib0048","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1200\/JCO.2000.18.20.3495","article-title":"Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations","volume":"18","author":"Avril","year":"2000","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.09.001_bib0049","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1200\/JCO.2002.20.2.379","article-title":"Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography","volume":"20","author":"Bos","year":"2002","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.09.001_bib0050","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1007\/s00259-015-3080-z","article-title":"Appearance of untreated bone metastases from breast cancer on FDG PET\/CT: importance of histologic subtype","volume":"42","author":"Dashevsky","year":"2015","journal-title":"Eur J Nucl Med Mol Img"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.09.001_bib0051","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2967\/jnumed.115.161455","article-title":"Comparison of 18F-FDG PET\/CT for systemic staging of newly diagnosed invasive lobular carcinoma versus invasive ductal carcinoma","volume":"56","author":"Hogan","year":"2015","journal-title":"J Nucl Med"},{"issue":"6797","key":"10.1053\/j.semnuclmed.2024.09.001_bib0052","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.09.001_bib0053","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/RLU.0000000000001724","article-title":"18F-FES PET has added value in staging and therapy decision making in patients with disseminated lobular breast cancer","volume":"42","author":"Venema","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.09.001_bib0054","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2967\/jnumed.120.247882","article-title":"Head-to-head evaluation of (18)F-FES and (18)F-FDG PET\/CT in metastatic invasive lobular breast cancer","volume":"62","author":"Ulaner","year":"2021","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.09.001_bib0055","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2214\/AJR.22.28809","article-title":"Prospective pilot study of (18)F-Fluoroestradiol PET\/CT in patients with invasive lobular carcinomas","volume":"221","author":"Covington","year":"2023","journal-title":"AJR Am J Roentgenol"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.09.001_bib0056","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.23435","article-title":"ER-Targeted PET for initial staging and suspected recurrence in ER-positive breast cancer","volume":"7","author":"Ulaner","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.09.001_bib0057","article-title":"16\u03b1-18F-fluoro-17\u03b2-estradiol PET\/CT-A tool for staging estrogen receptor-expressing breast cancer?","volume":"7","author":"O'Brien","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1053\/j.semnuclmed.2024.09.001_bib0058","article-title":"Fluorine-18-Labeled Fluoroestradiol PET\/CT: current status, gaps in knowledge, and controversies-ajr expert panel narrative review","author":"Covington","year":"2023","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.09.001_bib0059","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1158\/1078-0432.CCR-16-0362","article-title":"Estrogen receptor binding (18F-FES PET) and glycolytic activity (18F-FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer","volume":"23","author":"Kurland","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1053\/j.semnuclmed.2024.09.001_bib0060","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s12149-023-01871-8","article-title":"18)F-FES and (18)F-FDG PET\/CT imaging as a predictive biomarkers for metastatic breast cancer patients undergoing cyclin-dependent 4\/6 kinase inhibitors with endocrine treatment","volume":"37","author":"Liu","year":"2023","journal-title":"Ann Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.09.001_bib0061","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00259-023-06534-4","article-title":"Total-body PET\/CT or LAFOV PET\/CT? axial field-of-view clinical classification","volume":"51","author":"Mingels","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1140","key":"10.1053\/j.semnuclmed.2024.09.001_bib0062","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20220357","article-title":"Total-body PET: a new paradigm for molecular imaging","volume":"95","author":"Daube-Witherspoon","year":"2022","journal-title":"Br J Radiol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.09.001_bib0063","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2967\/jnumed.119.231845","article-title":"PennPET explorer: human imaging on a whole-body imager","volume":"61","author":"Pantel","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.09.001_bib0064","series-title":"Dual-Tracer Dynamic PET Imaging on the Long-Axial Field-Of-View PennPET Explorer: A Proof-Of-Principle Study With [18F]Fluoroglutamine and [18F]Fluorodeoxyglucose","author":"Kwon","year":"2023"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.09.001_bib0065","doi-asserted-by":"crossref","first-page":"djt337","DOI":"10.1093\/jnci\/djt337","article-title":"Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial","volume":"106","author":"Di Leo","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.09.001_bib0066","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1158\/2159-8290.CD-14-0697","article-title":"Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer","volume":"5","author":"van Kruchten","year":"2015","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1053\/j.semnuclmed.2024.09.001_bib0067","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1158\/1078-0432.CCR-16-2197","article-title":"18)F-Fluoroestradiol PET\/CT measurement of estrogen receptor suppression during a phase I trial of the novel estrogen receptor-targeted therapeutic GDC-0810: using an imaging biomarker to guide drug dosage in subsequent trials","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.09.001_bib0068","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s00259-016-3561-8","article-title":"Utility of (18)F-fluoroestradiol ( (18)F-FES) PET\/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy","volume":"44","author":"Lin","year":"2017","journal-title":"Eur J Nucl Med Mol Img"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.09.001_bib0069","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13058-020-01333-3","article-title":"A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using (18)F-FES PET\/CT imaging","volume":"22","author":"Jager","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.09.001_bib0070","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40164-018-0116-7","article-title":"Mechanisms for estrogen receptor expression in human cancer","volume":"7","author":"Hua","year":"2018","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.09.001_bib0071","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/pros.23446","article-title":"Estrogen receptor signaling in prostate cancer: Implications for carcinogenesis and tumor progression","volume":"78","author":"Bonkhoff","year":"2018","journal-title":"Prostate"},{"key":"10.1053\/j.semnuclmed.2024.09.001_bib0072","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3389\/fonc.2019.00359","article-title":"Anti-estrogen treatment in endometrial cancer: a systematic review","volume":"9","author":"van Weelden","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.09.001_bib0073","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00259-010-1589-8","article-title":"Functional oestrogen receptor \u03b1 imaging in endometrial carcinoma using 16\u03b1-[\u00b9\u2078F]fluoro-17\u03b2-oestradiol PET","volume":"38","author":"Tsujikawa","year":"2011","journal-title":"Eur J Nucl Med Mol Img"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.09.001_bib0074","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134969","article-title":"Endometrial endometrioid carcinoma metastases show decreased ER-alpha and PR-a expression compared to matched primary tumors","volume":"10","author":"Bartosch","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.09.001_bib0075","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/00006231-199707000-00003","article-title":"Oestrogen receptors in meningiomas: a correlative PET and immunohistochemical study","volume":"18","author":"MORESCO","year":"1997","journal-title":"Nuc Med Comms"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.09.001_bib0076","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2967\/jnumed.114.147579","article-title":"Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16\u03b1-18F-Fluoro-17\u03b2-Estradiol PET\/CT","volume":"56","author":"van Kruchten","year":"2015","journal-title":"J Nuc Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.09.001_bib0077","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1757-2215-2-7","article-title":"Positron emission tomography in ovarian cancer: 18F-deoxy-glucose and 16\u03b1-18F-fluoro-17\u03b2-estradiol PET","volume":"2","author":"Yoshida","year":"2009","journal-title":"J Ovarian Res"},{"issue":"12","key":"10.1053\/j.semnuclmed.2024.09.001_bib0078","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1111\/jog.13117","article-title":"Accuracy of a new diagnostic tool in deep infiltrating endometriosis: positron emission tomography-computed tomography with 16\u03b1-[18F]fluoro-17\u03b2-estradiol","volume":"42","author":"Cosma","year":"2016","journal-title":"J Obstet Gynaecol Res"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299824000771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299824000771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T21:23:32Z","timestamp":1731705812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299824000771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0001299824000771"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.09.001","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on 18F-Fluoroestradiol","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}